Tempus AI Inc.
Tempus AI Announces Acquisition of Ambry Genetics
Summary
Tempus AI, Inc. has entered into a Securities Purchase Agreement to acquire Ambry Genetics Corporation for $375.0 million in cash and the issuance of 4,843,136 shares of Tempus AI's Class A common stock, subject to customary closing conditions. In connection with the acquisition, Tempus AI has entered into a debt commitment letter with affiliates of Ares Capital Corporation for a $100.0 million senior secured revolving credit facility and additional term loans totaling $200.0 million. The acquisition is expected to close in the first quarter of 2025.
Get alerts for TEM
Be first to know when Tempus AI Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Tempus AI Inc.
Tempus AI Inc. is a pioneering technology company specializing in the development and application of artificial intelligence solutions across various industries. Its primary function is to harness AI-driven insights to enhance operational efficiency and decision-making processes for enterprises. Tempus AI Inc. is at the forefront of integrating machine learning into sectors such as healthcare, finance, and logistics, where predictive data analytics can provide substantial competitive advantages. The company delivers bespoke AI platforms that enable organizations to streamline complex data sets into actionable intelligence. Its expertise extends to natural language processing and computer vision, offering comprehensive AI tools that drive innovation and efficiency. As a significant player in the tech market, Tempus AI Inc. contributes to setting industry standards for AI deployment, impacting how businesses leverage intelligent technology to improve outcomes and strategic planning. Founded with a mission to propel the development of intelligent systems, Tempus AI Inc. remains a vital contributor to the digital transformation of multiple industries, facilitating the transition towards a more data-driven future.
Official SEC Documents
Advertisement